Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 23, 2015 11:47 PM ET

Biotechnology

Company Overview of Zenyaku Kogyo Co., Ltd.

Company Overview

Zenyaku Kogyo Co., Ltd. develops dermatological and anti-cancer drugs. Its product includes Rituxan™, an anti-CD20 antibody for the treatment of B-cell Non-Hodgkin's Lymphoma. The company also develops OTC drugs. Zenyaku Kogyo Co., Ltd. was founded in 1950 and is based in Tokyo, Japan.

5-6-15 Otsuka

Bunkyo-ku

Tokyo,  112-8650

Japan

Founded in 1950

Phone:

81 3 3946 1111

Fax:

81 3 3946 1130

Key Executives for Zenyaku Kogyo Co., Ltd.

Chief Executive Officer and President
Compensation as of Fiscal Year 2014.

Zenyaku Kogyo Co., Ltd. Key Developments

Anthera Pharmaceuticals, Inc. Enters into License Agreement with Zenyaku Kogyo Co., Ltd

On December 11, 2014, Anthera Pharmaceuticals Inc. entered into a license agreement with Zenyaku Kogyo Co., Ltd. pursuant to which the company granted Zenyaku an exclusive license to certain patent rights, know-how and other intellectual property relating to blisibimod. Under the agreement, Zenyaku obtained exclusive rights to develop, use, sell, have sold, offer for sale and import blisibimod and any related products containing any of blisibimod's binding domains, including but not limited to any pegylated blisibimod binding domain, certain rights to grant sublicenses and an option to expand the territory of the license to include China, Singapore, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia and South Korea. The licensed patent rights include all patents controlled by Anthera or its affiliates relating to blisibimod, including those licensed to Anthera under that certain License Agreement dated December 18, 2007 between Anthera and Amgen Inc. as amended October 16, 2009 and November 26, 2014. Anthera retained the right to practice and grant licenses relating to blisibimod technology in all areas outside of the licensed territory, to manufacture and have manufactured compounds and products relating to blisibmod anywhere in the world and to conduct or have conducted clinical trials and other studies of compounds and products relating to blisibmod anywhere in the world. The development activities of both Anthera and Zenyaku will be overseen by a joint development committee. Under the terms of the License Agreement, Zenyaku assumes sole responsibility for the sale, marketing, promotion and commercialization of products relating to blisibimod in the licensed territory, and is obligated to use commercially reasonable efforts to market, promote, sell and commercialize licensed products in such territory.

Similar Private Companies By Industry

Company Name Region
BioMedcore Inc. Asia
GeneQuest Inc. Asia
Narishige Co. Ltd. Asia
Amano Enzyme Inc. Asia
MicroBiopharm Japan Co., Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zenyaku Kogyo Co., Ltd., please visit www.zenyaku.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.